SG11201810522UA - Anti-cd40 antibodies and their uses - Google Patents
Anti-cd40 antibodies and their usesInfo
- Publication number
- SG11201810522UA SG11201810522UA SG11201810522UA SG11201810522UA SG11201810522UA SG 11201810522U A SG11201810522U A SG 11201810522UA SG 11201810522U A SG11201810522U A SG 11201810522UA SG 11201810522U A SG11201810522U A SG 11201810522UA SG 11201810522U A SG11201810522U A SG 11201810522UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibodies
- california
- pct
- diane
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 241001504505 Troglodytes troglodytes Species 0.000 abstract 1
- 229940126587 biotherapeutics Drugs 0.000 abstract 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000003499 redwood Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property C.--.` Organization 03 111111H111011111101011101011111001010111111001H0111111111111110111111111111 International Bureau (10) International Publication Number (43) International Publication Date ......P' WO 2017/205742 Al 30 November 2017 (30.11.2017) WIPO I PCT _ (51) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) (71) Applicant: ABBVIE BIOTHERAPEUTICS INC. (72) (74) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, PCT/US2017/034681 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 26 May 2017 (26.05.2017) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/342,417 27 May 2016 (27.05.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, [US/US]; 1500 Seaport Boulevard, Redwood City, Califor- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, nia 94063 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Inventors: HOLLENBAUGH, Diane; 1534 Fordham EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Way, Mountain View, California 94040 (US). YE, Shim- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, ing; 371 Loma Verde Avenue, Palo Alto, California 94306 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (US). COHEN, Diane Sau Mun; 924 Wren Drive, San KM, ML, MR, NE, SN, TD, TG). Jose, California 95125 (US). Agent: HOM, Roy et al.; Dechert LLP, 1095 Avenue of the Americas, New York, New York 10036-6797 (US). — = = = (54) Title: ANTI-CD40 ANTIBODIES AND THEIR USES : The present disclosure provides novel anti-CD40 antibodies, compositions including the antibodies, and methods of making and using the same. encoding CD40 Receptor (SEQ ID NO:40) (from EMBO J, 8(5), 1403-1410 (1989)) the new antibodies, nucleic acids = = = 10 20 30 40 50 MVRLPLQCVL WGCLLTAVHP EPPTACREKQ YLINSQCCSL CQPGQKLVSD 60 70 BO 90 100 CTEFTETECL PCGESEFLDT WNRETHCHQH KYCDPNLGLR VQQKGTSETD 110 120 130 140 150 TICTCEEGWH CTSEACESCV LHRSCSPGFG VKQIATGVSD TICEPCPVGF 160 170 180 190 200 FSNVSSAFEK CHPWTSCETK DLVVQQAGTN KTDVVCGPQD RLRALVVIPI 210 220 230 240 250 IFGILFAILL VLVFIKKVAK KPTNKAPHPK QEPQEINFPD DLPGSNTAAP 260 270 VQETLHGCQP VTQEDGKESR ISVQERQ = = === === = = = _ = = CD40 Ligand (SEQ ID NO:41) (from FEBS Letters, 315 (3), 259-266 (1993)) = = = 10 20 30 40 50 MIETYNQTSP RSAATGLPIS MKIFMYLLTV FLITQMIGSA LFAVYLERRL 60 70 BO 90 100 DKIEDERNLH EDFVFMKTIQ RCNTGERSLS LLNCEEIKSQ FEGFVKDIML 110 120 130 140 150 NKEETKKENS FEMQKGDQNP QIAAHVISEA SSKTTSVLQW AEKGYYTMSN 160 170 180 190 200 NLVTLENGKQ LTVKRQGLYY IYAQVTFCSN REASSQAPFI ASLCLKSPGR 210 220 230 240 250 FERILLRAAN THSSAKPCGQ QSIELGGVFE LQPGASVFVN VTDPSQVSHG 260 TGFTSFGLLK L — 11 rl 71' Ir---- un c> rl , IN ,-1 © (57) rl FIG. 1 [Continued on next page] WO 2017/205742 Al MIDEDIMOMMIDIRMEM00101011EMEDIEHIMEMOIMIE Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342417P | 2016-05-27 | 2016-05-27 | |
| PCT/US2017/034681 WO2017205742A1 (en) | 2016-05-27 | 2017-05-26 | Anti-cd40 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810522UA true SG11201810522UA (en) | 2018-12-28 |
Family
ID=59014833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810522UA SG11201810522UA (en) | 2016-05-27 | 2017-05-26 | Anti-cd40 antibodies and their uses |
| SG10201914132RA SG10201914132RA (en) | 2016-05-27 | 2017-05-26 | Anti-cd40 antibodies and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201914132RA SG10201914132RA (en) | 2016-05-27 | 2017-05-26 | Anti-cd40 antibodies and their uses |
Country Status (34)
| Country | Link |
|---|---|
| US (8) | US10519243B2 (en) |
| EP (2) | EP3995511A1 (en) |
| JP (2) | JP2019523221A (en) |
| KR (2) | KR20220028143A (en) |
| CN (1) | CN109476750B (en) |
| AR (2) | AR108611A1 (en) |
| AU (1) | AU2017271602A1 (en) |
| BR (1) | BR112018074468A2 (en) |
| CA (1) | CA3025347A1 (en) |
| CL (1) | CL2018003366A1 (en) |
| CO (1) | CO2018012699A2 (en) |
| CR (1) | CR20180605A (en) |
| CY (1) | CY1124806T1 (en) |
| DO (1) | DOP2018000258A (en) |
| EC (1) | ECSP18094829A (en) |
| ES (1) | ES2901722T3 (en) |
| HR (1) | HRP20211882T1 (en) |
| HU (1) | HUE056670T2 (en) |
| IL (1) | IL263223B2 (en) |
| LT (1) | LT3464361T (en) |
| MX (1) | MX2018014630A (en) |
| MY (1) | MY195442A (en) |
| NZ (1) | NZ748644A (en) |
| PE (1) | PE20190970A1 (en) |
| PH (1) | PH12018502456A1 (en) |
| PL (1) | PL3464361T3 (en) |
| PT (1) | PT3464361T (en) |
| RS (1) | RS62726B1 (en) |
| RU (1) | RU2752049C2 (en) |
| SG (2) | SG11201810522UA (en) |
| SI (1) | SI3464361T1 (en) |
| TW (2) | TWI761348B (en) |
| UA (1) | UA123111C2 (en) |
| WO (1) | WO2017205742A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3156538C (en) * | 2007-11-01 | 2023-12-12 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| HUE056670T2 (en) * | 2016-05-27 | 2022-02-28 | Abbvie Biotherapeutics Inc | Anti-cd40 antibodies and their uses |
| EP3781203A4 (en) * | 2018-04-20 | 2022-04-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| KR20210095891A (en) | 2018-11-23 | 2021-08-03 | 스트라이크 파마 아베 | bispecific conjugate |
| CA3120793A1 (en) * | 2018-11-30 | 2020-06-04 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof |
| CN111454361B (en) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | Antibodies that bind to CD40 and uses thereof |
| CN113811547B (en) | 2019-03-27 | 2024-06-25 | 国家医疗保健研究所 | Recombinant proteins with CD40 activating properties |
| CN113728008B (en) * | 2019-04-10 | 2024-04-09 | 南开大学 | anti-CD 40 antibodies and uses thereof |
| WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| JP2022553493A (en) * | 2019-09-11 | 2022-12-23 | ノバルティス アーゲー | Methods for Preventing Human Virus-Related Disorders in Patients |
| CN116057070A (en) * | 2019-10-23 | 2023-05-02 | 礼进生物医药科技（上海）有限公司 | anti-CD 40 binding molecules and bispecific antibodies comprising same |
| CA3157516A1 (en) * | 2019-11-08 | 2021-05-14 | Xinyan Zhao | Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof |
| KR20220109436A (en) * | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | Interferon-conjugated antigen binding proteins and uses thereof |
| GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| US20230346966A1 (en) * | 2020-07-23 | 2023-11-02 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| CN115403670A (en) * | 2021-05-26 | 2022-11-29 | 安徽瀚海博兴生物技术有限公司 | anti-CD40 antibodies and uses thereof |
| WO2024059899A1 (en) * | 2022-09-20 | 2024-03-28 | Currus Biologics Pty Ltd | Bispecific polypeptides and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE275198T1 (en) | 1991-12-02 | 2004-09-15 | Medical Res Council | PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| CZ294425B6 (en) | 1997-04-14 | 2005-01-12 | Micromet Ag | Process for preparing anti-human antigen receptor, anti-human antigen receptor per se, VH and VL chain, kit for the selection of anti-human antigen receptors and pharmaceutical composition containing such a receptor |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| PT1135498E (en) | 1998-11-18 | 2008-04-30 | Genentech Inc | Antibody variants with higher binding affinity compared to parent antibodies |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU3662101A (en) | 2000-02-01 | 2001-08-14 | Tanox Inc | Cd40-binding apc-activating molecules |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1707627B1 (en) * | 2003-12-25 | 2012-11-14 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic anti-CD40 antibody mutant |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2573293A1 (en) * | 2004-07-10 | 2006-02-16 | Alexion Pharmaceuticals, Inc. | Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| EP2066349B1 (en) * | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
| NZ601858A (en) * | 2007-10-05 | 2014-03-28 | Genentech Inc | Methods and compositions for diagnosis and treatment of amyloidosis |
| KR101760242B1 (en) * | 2010-03-31 | 2017-07-21 | 베링거 인겔하임 인터내셔날 게엠베하 | Anti-cd40 antibodies |
| CN113461819B (en) | 2011-04-29 | 2024-01-02 | 埃派斯进有限公司 | anti-CD 40 antibodies and methods of use thereof |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| CA2882272C (en) | 2012-08-24 | 2023-08-29 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc region variant |
| DK2914627T3 (en) * | 2012-10-30 | 2021-07-12 | Apexigen Inc | ANTI-CD40 ANTIBODIES AND METHODS OF USE |
| JP6449229B2 (en) * | 2013-03-15 | 2019-01-09 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | FC variant |
| GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
| SG10201913099YA (en) | 2014-10-29 | 2020-02-27 | Seattle Genetics Inc | Dosage and administration of non-fucosylated anti-cd40 antibodies |
| DK3303395T3 (en) * | 2015-05-29 | 2020-01-27 | Abbvie Inc | ANTI-CD40 ANTIBODIES AND APPLICATIONS THEREOF |
| HUE056670T2 (en) * | 2016-05-27 | 2022-02-28 | Abbvie Biotherapeutics Inc | Anti-cd40 antibodies and their uses |
| BR112018074453A2 (en) * | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
-
2017
- 2017-05-26 HU HUE17728411A patent/HUE056670T2/en unknown
- 2017-05-26 PT PT177284114T patent/PT3464361T/en unknown
- 2017-05-26 SI SI201731001T patent/SI3464361T1/en unknown
- 2017-05-26 TW TW106117521A patent/TWI761348B/en active
- 2017-05-26 LT LTEPPCT/US2017/034681T patent/LT3464361T/en unknown
- 2017-05-26 NZ NZ748644A patent/NZ748644A/en unknown
- 2017-05-26 MX MX2018014630A patent/MX2018014630A/en unknown
- 2017-05-26 AU AU2017271602A patent/AU2017271602A1/en active Pending
- 2017-05-26 PL PL17728411T patent/PL3464361T3/en unknown
- 2017-05-26 US US15/606,227 patent/US10519243B2/en active Active
- 2017-05-26 EP EP21200482.4A patent/EP3995511A1/en not_active Withdrawn
- 2017-05-26 SG SG11201810522UA patent/SG11201810522UA/en unknown
- 2017-05-26 TW TW111109284A patent/TWI814279B/en active
- 2017-05-26 UA UAA201812784A patent/UA123111C2/en unknown
- 2017-05-26 JP JP2018561225A patent/JP2019523221A/en not_active Withdrawn
- 2017-05-26 BR BR112018074468-9A patent/BR112018074468A2/en unknown
- 2017-05-26 KR KR1020227005372A patent/KR20220028143A/en active Application Filing
- 2017-05-26 IL IL263223A patent/IL263223B2/en unknown
- 2017-05-26 CA CA3025347A patent/CA3025347A1/en active Pending
- 2017-05-26 ES ES17728411T patent/ES2901722T3/en active Active
- 2017-05-26 MY MYPI2018002113A patent/MY195442A/en unknown
- 2017-05-26 CN CN201780046023.8A patent/CN109476750B/en active Active
- 2017-05-26 AR ARP170101447A patent/AR108611A1/en unknown
- 2017-05-26 PE PE2018003115A patent/PE20190970A1/en unknown
- 2017-05-26 KR KR1020187037322A patent/KR102366355B1/en active IP Right Grant
- 2017-05-26 WO PCT/US2017/034681 patent/WO2017205742A1/en active Application Filing
- 2017-05-26 RS RS20211552A patent/RS62726B1/en unknown
- 2017-05-26 RU RU2018146533A patent/RU2752049C2/en active
- 2017-05-26 CR CR20180605A patent/CR20180605A/en unknown
- 2017-05-26 SG SG10201914132RA patent/SG10201914132RA/en unknown
- 2017-05-26 EP EP17728411.4A patent/EP3464361B1/en active Active
- 2017-05-26 HR HRP20211882TT patent/HRP20211882T1/en unknown
-
2018
- 2018-02-21 US US15/901,560 patent/US10023645B1/en active Active
- 2018-07-16 US US16/036,691 patent/US10400041B2/en active Active
- 2018-11-22 PH PH12018502456A patent/PH12018502456A1/en unknown
- 2018-11-26 CL CL2018003366A patent/CL2018003366A1/en unknown
- 2018-11-26 CO CONC2018/0012699A patent/CO2018012699A2/en unknown
- 2018-11-26 DO DO2018000258A patent/DOP2018000258A/en unknown
- 2018-12-21 EC ECSENADI201894829A patent/ECSP18094829A/en unknown
-
2019
- 2019-09-03 US US16/559,504 patent/US10844131B2/en active Active
- 2019-10-21 US US16/659,209 patent/US10597460B2/en active Active
-
2020
- 2020-10-16 US US17/073,150 patent/US20210024642A1/en not_active Abandoned
-
2021
- 2021-05-21 US US17/327,264 patent/US20210277137A1/en not_active Abandoned
- 2021-12-03 CY CY20211101058T patent/CY1124806T1/en unknown
- 2021-12-30 US US17/566,149 patent/US20220119542A1/en not_active Abandoned
-
2022
- 2022-01-24 AR ARP220100135A patent/AR124692A2/en unknown
- 2022-02-18 JP JP2022023569A patent/JP7331179B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810522UA (en) | Anti-cd40 antibodies and their uses | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201903298PA (en) | Method and apparatus for configuring subband aggregation in nr carrier in wireless communication system | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201903331QA (en) | Restimulation of cryopreserved tumor infiltrating lymphocytes | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807770RA (en) | Sequence arrangements and sequences for neoepitope presentation | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201901959YA (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof |